Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.

@article{Nieto1999AcuteEA,
  title={Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.},
  author={Yago L. Nieto and Pablo J Cagnoni and Scott I. Bearman and Elizabeth J Shpall and Steve Matthes and T DeBoom and Anna E Baron and R Barry Jones},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1999},
  volume={5 3},
  pages={501-6}
}
The purpose of this study was to describe acute encephalopathy as a new toxicity associated with paclitaxel, when it is delivered at high doses (> or =600 mg/m2) with stem cell support. A total of 129 patients, included in clinical trials of paclitaxel-containing high-dose chemotherapy, were analyzed. A total of 114 patients received paclitaxel at a dose of > or =600 mg/m2. Six patients presented acute encephalopathy starting between 7 and 23 days after paclitaxel treatment; two of them had… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Iatrogenic neurology.

Handbook of clinical neurology • 2014
View 11 Excerpts
Highly Influenced

On pushing the outer edge of the outer edge of paclitaxel's dosing envelope.

Clinical cancer research : an official journal of the American Association for Cancer Research • 1999
View 5 Excerpts
Highly Influenced

Hepatic encephalopathy.

Emergency medicine clinics of North America • 2009
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Phase I trial of high-dose paclitaxel in combination with cyclophosphamide, thiotepa and carboplatin with autologous peripheral blood stem cell rescue

J. I. Mayordomo, A. Yubero, +8 authors A. Tres
Proc. Am. Soc. Clin. Oncol., • 1997

Pulmonary toxicity secondary to paclitaxel-containing high-dose chemotherapy

P. J. Cagnoni, Y. Nieto, +5 authors R. B. Jones
Proc. Am. Soc. Clin. Oncol.,16: • 1997
View 1 Excerpt

High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1996
View 8 Excerpts

A Phase I dose escalation trial of high dose Taxol, Novantrone and thiotepa (TNT) followed by autologous stem cell rescue: toxicity

K. Fields, J. Perkins, +5 authors L. Kronish
Proc. Am. Soc. Clin. Oncol., • 1995

Similar Papers

Loading similar papers…